FDA Approves Abemaciclib for HR+/HER2- Breast Cancer

September 28, 2017 – The FDA approved abemaciclib for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy. The CDK4/6 inhibitor has also been approved as a monotherapy for patients with HR+/HER2- breast cancer with metastatic disease who have previously received endocrine therapy and chemotherapy. Support for the combination indication comes from the phase III MONARCH 2 … (leggi tutto)